What is PepperLime Health Acquisition Corporation (PEPL)'s fair-value range?

EvidInvest reads PepperLime Health Acquisition Corporation (PEPL)'s market price back into the assumptions behind it — the implied P/E, growth rate and cash yield — using its latest filed financials, then lets you set your own. See the full DCF, Graham number, EPV and multiple-based methods at https://evidinvest.com/valuation/PEPL.

How is PepperLime Health Acquisition Corporation (PEPL)'s fair value calculated?

PepperLime Health Acquisition Corporation (PEPL)'s fair value is computed with several independent methods — a discounted cash flow (DCF) model, the Graham number, earnings power value (EPV), and valuation multiples (PE, EV/EBITDA, P/S, P/B) benchmarked against its industry — using data from SEC filings.

What is PepperLime Health Acquisition Corporation (PEPL)'s PE ratio versus its industry?

EvidInvest shows PepperLime Health Acquisition Corporation (PEPL)'s current and historical PE ratio alongside its sector and industry averages, so you can see whether the stock trades at a premium or discount to peers. Full breakdown at https://evidinvest.com/valuation/PEPL.

Fair value · PepperLime Health Acquisition Corporation (PEPL) · updated 2026-10-03 · from 10-K FY2022

PepperLime Health Acquisition trades at $10.93. That price implies a P/E of 54.7× and 10.0% yearly EPS growth for a decade.

Previous close

Are those assumptions reasonable? Use PEPL’s filed growth history and the AI chat to decide, then set your own inputs below — the range you build is yours.

What the price implies

P/E: 54.7×
EPS growth: 10.0%

Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings. This price: Previous close.

Set your own assumptions ↓See how each method got its number Check another stock

The filing behind these numbers

PepperLime Health Acquisition Corporation

Revenue: $0
Diluted EPS: $0.19
Free cash flow: $-436249; operating cash flow − capital expenditure
Diluted shares: 17.0M; weighted average

10-K FY2022 · fiscal year ended 2022-12-31 · filed 2023-03-28

Trailing-twelve-month EPS also uses the quarterly 10-Qs through Q3 FY2023 (filed 2023-11-13).

Open the 10-K list on sec.govCIK 1873324

Valuation tool: build your own PEPL range

Fair Value Summary

Range implied by today’s price3 of 8 methods

$11 – $11

Price $10.93

Bear $11Base $11Bull $11

Range with preset inputs

$2.42 – $2.42

Price $10.93

Bear $2.42Base $2.42Bull $2.42

Every method that could be solved backwards opens on the assumption today’s price makes, so the top range sits on the price — that is arithmetic, not a view. Change any input and it becomes yours.

We don’t tell you what PEPL is worth. Every tab OPENS on what today’s price implies for that method’s key assumption; you decide whether that assumption is reasonable — the growth matrix has PEPL’s filed history and the AI chat will reason it through with you — and the range you build is yours. Our presets are filed history and reference settings, never a recommendation.

Discounted cash flow

N/A

No revenue in the latest annual filing

Preset inputs — revenue-driven DCF from the latest filing

• No revenue in the latest annual filing

Implied by today’s price

Starting free cash flow is not positive; the model has nothing to grow, so no growth rate reaches the price.

Not solvable from the price — Starting free cash flow is not positive; the model has nothing to grow, so no growth rate reaches the price. Showing preset inputs.

This method has no key input to read out of the price. The others below do, and you set them yourself: the growth matrix shows what PEPL has actually filed, and the AI chat will reason it through with you.

Your inputs

Free cash flow grows at your stage-1 rate, then your stage-2 rate, then a terminal rate; everything is discounted at your WACC.

Stage-1 growth5.0%

Yearly free-cash-flow growth for the first stage. Starts below zero so a shrinking-cash-flow case — and the rate today’s price implies — can be set.

-20.0%60.0%

Stage-1 years5 yrs

How long stage-1 growth lasts.

1 yrs10 yrs

Stage-2 growth2.5%

Slower growth after stage 1, before the terminal phase.

-20.0%30.0%

Stage-2 years5 yrs

0 yrs10 yrs

Terminal growth2.5%

Growth forever after the two stages. Above ~3% is rarely justified.

0.0%5.0%

Discount rate (WACC)9.00%

The return you require. Default is the WACC EvidInvest computed for this company. Higher discount rate, lower value.

3.00%15.00%

Net debt ($M)Debt minus cash, from the balance sheet. Subtracted from enterprise value.

Starting FCF ($M)Latest free cash flow from the filing (operating cash flow minus capex).

Shares (M)Diluted shares, from the filing.

Year by year (two-stage model, $M)

PV explicit $0M · PV terminal $-0M · EV $0M · equity $1M

Year	Stage	FCF	Present value
1	Stage 1	$-0M	$-0M
2	Stage 1	$-0M	$-0M
3	Stage 1	$-0M	$-0M
4	Stage 1	$-0M	$-0M
5	Stage 1	$-0M	$-0M
6	Stage 2	$-0M	$-0M
7	Stage 2	$-0M	$-0M
8	Stage 2	$-0M	$-0M
9	Stage 2	$-0M	$-0M
10	Stage 2	$-0M	$-0M

Inputs from the filing

Free cash flow: $-808427; sum of the last four quarters
EBIT: $-1.1M; latest annual
Shares: 17.0M
Total debt: $0
Cash: $891154
Net debt: $-891154; debt − cash

10-K FY2022 · period ended 2022-12-31 · filed 2023-03-28 · sec.gov

Prefer a blank slate with reverse DCF? Open the standalone DCF / reverse DCF for PEPL

Loading history...

Download the full PEPL valuation report (PDF) — free

DCF fair value, Graham number, EPV, key multiples and growth rates in one clean PDF.

PepperLime Health Acquisition trades at $10.93. That price implies a P/E of 54.7× and 10.0% yearly EPS growth for a decade.

The filing behind these numbers

Valuation tool: build your own PEPL range

Range implied by today’s price3 of 8 methods

Range with preset inputs

Your inputs

Year by year (two-stage model, $M)

More on PEPL

Compare with peers

Explore

Valuation tool: build your own PEPL range

Range implied by today’s price3 of 8 methods

Range with preset inputs

Your inputs

Year by year (two-stage model, $M)

More on PEPL

Compare with peers

Explore